Hyunho Jung
Hyunho Jung is Chief Executive Officer of Medytox. His role connects Medytox’s Korean manufacturing base, multi-product toxin portfolio, and overseas expansion strategy.
Jung’s company-level context matters because Medytox is not represented by a single toxin brand. The company is associated with Meditoxin / Neuronox, INNOTOX, Coretox, NEWLUX, and development-stage or region-specific product names. Jung therefore anchors the company-level story rather than a single product-origin claim.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Medytox |
| Current role | Chief Executive Officer |
| Company base | South Korea |
| Relevant company | Medytox |
| Relevant products | Meditoxin / Neuronox, INNOTOX, Coretox, NEWLUX |
| Official company source | Medytox: About Medytox 🔗 |
Career Notes
Section titled “Career Notes”- Medytox identifies Hyunho Jung as Chief Executive Officer on its English company overview.
- Medytox was established on May 2, 2000 and later became a KOSDAQ-listed Korean biopharmaceutical company.
- Medytox company materials describe botulinum toxin products and hyaluronic acid filler products as main product areas.
- The company’s public materials connect its toxin business to Korean manufacturing sites, a Gwanggyo R&D Center, a Seoul Global Business Center, and overseas entities or joint ventures.
Medytox Portfolio Context
Section titled “Medytox Portfolio Context”Jung is most relevant as Medytox company context. Medytox’s toxin relevance comes from several product lines rather than one global brand. Meditoxin / Neuronox provides the early Korean toxin-manufacturing anchor; INNOTOX adds liquid-formulation context; Coretox adds a separate product line framed around the active neurotoxin component; and NEWLUX represents a newer Korean product cycle.
Those relationships should stay product-specific. Jung’s leadership role does not make Medytox products interchangeable with Botox, Dysport, Xeomin, Jeuveau, Letybo, Daxxify, or another toxin product. Approval status, presentation, indications, unit language, and availability remain tied to each product and market.
Activity and Public Context
Section titled “Activity and Public Context”Medytox’s company materials frame the business around global expansion, botulinum toxin products, fillers, manufacturing capacity, R&D, and international entities. Recent market-expansion reporting linked from Medytox’s own news page has also described overseas registration and development activity around NEWLUX and MT10109L.
Those items are best read as company strategy and regulatory-development context. They should not be turned into approval claims unless a regulator, label, or official market-specific record supports that status.